Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering

The new drug for type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is reversible inhibitor of SGLT-2, leading to reduction of renal glucose reabsorption and decrease of plasma glucose, in an insulin-independent manner. In addition to glucose control, the management of coronary...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Hidekatsu, Katsuyama, Hisayuki, Hamasaki, Hidetaka, Adachi, Hiroki, Moriyama, Sumie, Yoshikawa, Reo, Sako, Akahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676340/
https://www.ncbi.nlm.nih.gov/pubmed/26668677
http://dx.doi.org/10.14740/jocmr2385w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676340/
https://www.ncbi.nlm.nih.gov/pubmed/26668677
http://dx.doi.org/10.14740/jocmr2385w

Ejemplares similares